We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senetek announced that Plethora Solutions, Senetek's exclusive licensee for its patented erectile dysfunction drug Invicorp in North America, has said that, following positive discussions with the FDA, Plethora Solutions intends to initiate the final component of the clinical development program for Invicorp in the U.S. in the second quarter of this year.
GlaxoSmithKline (GSK) has announced the start of an international Phase IIItrial of its investigational cancer treatment Tykerb (lapatinib) in squamous-cellcarcinoma of the head and neck (SCCHN).
Threshold Pharmaceuticals announced that a Phase III trial of glufosfamide did not show a statistically significant improvement in overall survival compared with best supportive care (BSC) in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy.
Shire and its collaborative partner New River Pharmaceuticals announced that the FDA has approved Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Novartis announced it has received an approvable letter from the FDA for Galvus (vildagliptin), which is being reviewed as a new once-daily oral treatment for patients with Type 2 diabetes.
Roche announced it is temporarily suspending recruitment into its Phase II dose-finding study using its investigational drug C.E.R.A. in anaemic patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy.